

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Anticonvulsants, Dravet Syndrome PDL Edit
<b>First Implementation Date:</b>	TBD
<b>Proposed Date:</b>	December 17, 2020
<b>Prepared For:</b>	MO HealthNet
<b>Prepared By:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input checked="" type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** As of June 2020, the FDA has granted authorization of three pharmacologic therapies for the treatment of Dravet syndrome (DS): Diacomit<sup>®</sup>, Epidiolex<sup>®</sup>, and Fintepla<sup>®</sup>. DS, a rare genetic form of epilepsy afflicting 1 in 15,700 births in the United States appears during the first year of life in otherwise healthy infants as a prolonged seizure with fever. Quality of life for an individual with DS can be severely impacted as the condition is often associated with a multitude of comorbidities including frequent and prolonged seizures, developmental delays and, chronic infections. While Epidiolex is approved for use in patients 1 year of age and older, Fintepla and Diacomit are only indicated in patients 2 and older and the latter must be used in combination with clobazam. Fintepla is only available through a REMS program that requires echocardiograms before, during, and after therapy.

Of the three agents for DS, Epidiolex is the only product with additional indications of Lennox-Gastaut syndrome (LGS) and Tuberous sclerosis complex (TSC). While LGS is also a form of epilepsy, TSC is a genetic condition that results in the formation of non-cancerous tumors in various parts of the body such as the brain, kidney, heart, eyes, lungs, and skin. Both are considered rare conditions with LGS accounting for 1-4% of all childhood epilepsy cases and TSC affecting approximately 40,000 to 80,000 individuals in the US. Although all three agents appear to exert their therapeutic effects via varying methods, their exact mechanisms of actions are not thoroughly understood. Phase III clinical trials seeking additional indications in the anti-epileptic field are currently underway for both Epidiolex and Fintepla,

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> <li>Epidiolex<sup>®</sup></li> </ul>	<ul style="list-style-type: none"> <li>Diacomit<sup>®</sup></li> <li>Fintepla<sup>®</sup></li> </ul>

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent<sup>™</sup> and Conduent Design<sup>™</sup> are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

## Setting & Population

- Drug class for review: Anticonvulsants, Dravet Syndrome
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Documented compliance on current preferred therapy regimen **OR**
- Failure to achieve desired therapeutic outcomes with trial of 1 preferred agent
  - Documented trial period of preferred agents
  - Documented ADE/ADR to preferred agents **OR**
- For Epidiolex:
  - Documented diagnosis of Dravet Syndrome, Lennox-Gastaut syndrome (LGS), or Tuberous sclerosis complex (TSC) in the past year **AND**
  - Trial of 2 or more anti-epileptic agents (includes clobazam, clonazepam, felbamate, lamotrigine, rufinamide, topiramate, valproate derivatives, or vigabatrin) **OR**
- For Non-Preferred Agents:
  - Participant aged 2 years or older **AND**
  - Documented diagnosis of Dravet syndrome **AND**
  - Documented therapeutic trial (defined as 30 days) of both valproate and clobazam **AND**
  - For Fintepla: Documented therapeutic trial of Diacomit (defined as 30 days) **AND**
  - Documentation of the baseline seizure frequency and duration **AND**
  - Initial approval of prior authorization is for 6 months, renewal of prior authorization may be up to 1 year with documentation of reduced seizure burden or improvement in quality of life using a validated scale for the disease state

## Denial Criteria

- Lack of adequate trial on required preferred agents
- For Diacomit and Fintepla: Documentation of moderate to severe hepatic or renal impairment
- For Fintepla: Documented history of MAOI therapy in the past 45 days
- Therapy will be denied if all approval criteria are not met
- Claim exceeds quantity limitations:

Drug Description	Generic Equivalent	Max Dosing Limitation
DIACOMIT 250 MG CAPSULE	STIRIPENTOL	12 capsules per day
DIACOMIT 250 MG POWDER PACKET	STIRIPENTOL	12 packets per day
DIACOMIT 500 MG CAPSULE	STIRIPENTOL	6 capsules per day
DIACOMIT 500 MG POWDER PACKET	STIRIPENTOL	6 packets per day
EPIDIOLEX 100 MG/ML SOLUTION	CANNABIDIOL	200 mL per fill
FINTEPLA 2.2 MG/ML SOLUTION	FENFLURAMINE	<ul style="list-style-type: none"> <li>• With concomitant Diacomit: 17 mg per day</li> <li>• Without concomitant Diacomit: 26 mg per day</li> </ul>

## Required Documentation

Laboratory Results:   
 MedWatch Form:

Progress Notes:   
 Other:

### SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

## Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)  
Rule Type: PDL

## Default Approval Period

1 year

## References

1. FINTEPLA® (fenfluramine) [package insert]. Emeryville CA: Zogenix, Inc.; June 2020.
2. DIACOMIT® (stiripentol) [package insert]. Gentilly, France: Biocodex; May 2020.
3. EPIDIOLEX® (cannabidiol) [package insert]. Carlsbad, CA: Greenwich Biosciences, Inc.; October 2020.
4. Wirrell EC, Laux L, Donner E, et al. Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel. *Pediatr Neurol.* 2017;68:18-34.e3. doi:10.1016/j.pediatrneurol.2017.01.025.
5. Dravet Syndrome Foundation. What is Dravet Syndrome? <https://www.dravetfoundation.org/what-is-dravet-syndrome/>. Accessed July 16, 2020.
6. Epilepsy Foundation. Dravet Syndrome. <https://www.epilepsy.com/learn/types-epilepsy-syndromes/dravet-syndrome>. Accessed July 16, 2020.
7. Children's Hospital of Philadelphia. Dravet Syndrome. <https://www.chop.edu/conditions-diseases/dravet-syndrome>. Accessed July 16, 2020.
8. IPD Analytics. New Drug Review: Fintepla (fenfluramine) oral solution, CIV. July 2020.
9. Evidence-Based Medicine and Fiscal Analysis: "Anticonvulsants, Dravet Syndrome – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; October 2020.
10. Evidence-Based Medicine Analysis: "Anticonvulsants, Dravet Syndrome Agents", UMKC-DIC; October 2020.

### SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.